1、 中办、国办印发《关于健全资源环境要素市场化配置体系的意见》，深化资源环境要素市场化配 置改革。意见提出，到2027年，碳排放权、用水权交易制度基本完善，排污权交易制度建立健全，节 能市场化机制更加健全，资源环境要素交易市场更加活跃、价格形成机制更加健全，推动资源环境要 素畅通流动、高效配置，充分释放市场潜力，对实现相关资源环境目标的支撑作用有效增强。 2、 记者从中国轻工业联合会了解到，1至4月，规模以上轻工企业实现营业收入7.35万亿元，同比增 长4.9%；实现利润4190.6亿元，同比增长3.8%。在系列扩内需、促消费政策支持下，轻工业经济运行 延续稳中有进态势。 3、 财政部拟第三次续发行2025年超长期特别国债（二期）。本次续发行国债为30年期固定利率附息 债。本次续发行国债竞争性招标面值总额710亿元，不进行甲类成员追加投标。本次续发行国债票面利 率与之前发行的同期国债相同，为1.88%。本次续发行国债的起息日、兑付安排与之前发行的同期国 债相同。 今日导读 4、5月28日，深圳市住房和建设局网站发布《深圳市配售型保障性住房管理办法（征求意见稿）》 《深圳市保障性住房规划建设管理办法（修订征求 ...

Group 1 - The core viewpoint of the articles highlights a strong performance in the Hong Kong pharmaceutical and biotechnology sector, with the Hang Seng Healthcare Index rising by 1.69% and reaching over 2.2% at one point [1] - The Hang Seng Medical Index ETF (159557) saw an increase of 1.34% with a trading volume exceeding 11 million, indicating active trading [1] - Notable stock performances include Green Leaf Pharmaceutical rising over 10%, and several other companies like Haijia Medical and Kangzhe Pharmaceutical increasing by over 8% [1] Group 2 - The issuance of 225 million shares by Hengrui Medicine in Hong Kong led to a stock price increase of over 33% during trading [1] - The current market environment suggests a focus on innovative drugs in Hong Kong, driven by the potential for excess returns as companies establish global competitive advantages [2] - The global competitive advantage of Chinese innovative drugs is becoming more apparent, with significant growth in License-out transactions in overseas markets [2] Group 3 - Recent policy and regulatory changes are favorable for the sector, including optimization of centralized procurement rules and increased support for innovative drugs [2] - Financially, leading Hong Kong innovative pharmaceutical companies are benefiting from increased License-out volumes, resulting in steady revenue and profit growth [2] - The valuation of the pharmaceutical sector remains relatively safe compared to other growth industries, indicating a favorable investment environment [2]

Group 1 - The Hong Kong pharmaceutical ETF (513700.SH) increased by 3.14%, with major constituents such as Xintai Medical rising by 60%, Meizhong Jiahe by 26%, and Nuocheng Jianhua by 13% [1] - Yuan Da Pharmaceutical announced a milestone breakthrough in its clinical research for the innovative radioactive nuclide-conjugated drug (RDC) GPN02006 for diagnosing hepatocellular carcinoma (HCC), achieving high-quality imaging within 30 minutes of administration [1] - GPN02006 provides strong molecular imaging evidence for personalized treatment plans, addressing the clinical need for rapid diagnosis of HCC and improving early diagnosis rates and monitoring of recurrence and metastasis [1] Group 2 - Guojin Securities believes that innovative drugs in the Hong Kong stock market will be a key investment theme in 2025, driven by AI enabling shorter R&D cycles, reduced costs, and improved efficiency [2] - The recovery of investment and financing activities in the global pharmaceutical industry is beneficial for improving cash flow for innovative drug companies [2] - Anticipation of fiscal stimulus, including the imminent release of the "Class B Directory," may catalyze valuation and sentiment recovery in the sector [2]